CervoMed Inc. (LS:A3ES01) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Closed: US$10M raised · US$4 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Jun 22, 2026 |
| Registered direct offering of common stock Announced: US$10M · US$4 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Jun 18, 2026 |
| Private placement of units (common stock or pre-funded warrant, Series B warrant and Series C warrant) Announced: about US$10.5M · US$3.14 a unit · Warrants at US$3.32 Buyers: Joshua S. Boger; Trusts related to John J. Alam and Sylvie Grégoire Insiders: Supported by insiders including board chair Joshua S. Boger and trusts related to CEO John J. Alam and director Sylvie Grégoire Use of proceeds: Research and development of neflamapimod, working capital and general corporate purposes | Jun 10, 2026 |